A growing body of clinical and experimental evidence implicates placental growth factor (PlGF) in pathologies, such as abnormal blood vessel formation and cancer progression ([@bib12]; [@bib26]; [@bib17], [@bib18]), including breast cancer ([@bib38]). The PlGF is a member of the vascular endothelial growth factor (VEGF) family first isolated from the placenta, but later found to be normally expressed during wound healing and in the thyroid ([@bib31]; [@bib33]; [@bib29]). In cancer cells, PlGF mediates a number of cellular activities that promote metastasis, including attraction of endothelial cells for establishment of a blood supply, enhanced invasiveness, and cellular movement ([@bib48]; [@bib7]; [@bib49]). In all 30--50% of human breast cancers express constitutive PlGF and its expression can be induced *de novo* in other PlGF-negative tumour cells that survive radioimmunotherapy ([@bib47]; [@bib49]).

Alteration of growth factor receptor type or frequency, such as HER2/neu in breast cancer, is associated with poor prognosis or metastasis. The three known PlGF receptors are the receptor tyrosine kinase (RTK) Flt-1 (also designated as VEGFR1), and the glycosylphosphatidylinositol-anchored co-receptors, neuropilin-1 and -2 (NRP-1, NRP-2). Flt-1 is ectopically expressed by breast cancer tissue, blood vessels, and breast cancer cell lines, in contrast to normal breast tissue, in which NRP-1 is present and Flt-1 is absent or near background ([@bib45]; [@bib49]). Therefore, it is possible that Flt-1 transmits PlGF signals, including those that lead to enhanced motility, in breast cancer.

Cellular motility is essential in the metastatic process, which requires cellular migration away from the primary tumour, invasion of surrounding tissue, entrance into the circulation, and then migration into a distant organ or tissue. It is not surprising then that alterations in cytoskeletal components responsible for motility mark the progression from a normal to neoplastic and then to a metastatic phenotype ([@bib5]). The cytoskeleton is composed of three elements, actin microfilaments, microtubules, and intermediate filaments (IFs). Some pro-metastatic growth factors, such as epidermal growth factor, cause actin microfilaments to disassemble stress fibres, restructure focal adhesion complexes, and form actin-containing lamellipodia and filopodia for migration ([@bib41]; [@bib19]). The PlGF, as it stimulates cellular migration, may also be a pro-metastatic growth factor.

The IFs, which include cytokeratins (CKs) and vimentin, are structural components that allow cells and tissue to endure stress, but IFs also participate in other cellular functions ([@bib21]; [@bib36]). These proteins vary according to cell type and cellular differentiation stage in normal tissue, and are often dysregulated in primary cancers and cancer cell lines. The specific intracellular consequences of altered IF expression are uncertain, but it has been shown that co-expression of certain CKs and vimentin augments carcinoma cell motility ([@bib13]; [@bib11]; [@bib22]; [@bib50]), and this was demonstrated more specifically in a recent report by [@bib43]. CK8, CK18, and CK19 are expressed by normal breast tissue, but often CK19 predominates in the progression to malignancy, and its expression with vimentin, a mesenchymal IF, which is not normally expressed by epithelium, is indicative of poor outcome ([@bib5]). This may be due to its role in promoting cellular mechanical stability, its participation in cellular movement, and its recently established role in stabilising invadopodia of metastasising cells ([@bib14]; [@bib43]).

The changes in cytoskeletal microfilament and IF necessary for migration or metastasis of cancer cells can be mediated through activation of a number of intracellular pathways ([@bib52]). Common intracellular targets of activated RTKs are the extracellular-regulated kinases (ERKs) and phosphotidylinositiol-3-kinase (PI3K).

In a previous report, we investigated PlGF/Flt1 inhibition using the PlGF/Flt-1-expressing MDA-MB-231 xenograft metastatic model, and the PlGF receptor-inhibiting peptide, BP-1. Treatment with BP-1 was sufficient to inhibit the formation of pulmonary metastases in mice implanted with MDA-MB-231 ([@bib49]). Using tissue microarrays it was also observed that 30--50% of primary breast cancers express PlGF, Flt-1, or both, whereas normal breast tissue expressed neither. Expression of Flt-1 was not confined to the blood vessels, but was also on tumour cells, and on breast tumour cell lines. This suggested that PlGF may not only serve as an angiogenic factor, which it is, but may also directly affect tumour cells expressing Flt-1. Evidence for the effect of PlGF on tumours is also offered by clinical data documenting that PlGF expression by human tumours, including breast cancers, is predictive of poor clinical outcome, which is characterised by aggressive disease, post-treatment recurrence, and metastases ([@bib9]; [@bib38]; [@bib54]; [@bib26]; [@bib15]).

This paper documents the results of *in vitro* analyses to determine how PlGF promotes cellular motility. To do this, the activation of several kinases by PlGF was investigated. The other goal of this study was to determine how the peptide, BP-1, which demonstrates anti-motility activity *in vitro* and anti-metastatic activity in breast cancer xenograft models, exerts its anti-tumour effects ([@bib49]). The focus is on early changes in cellular motility occurring within 1--3 h of exposure to PlGF. The aggressive breast cancer cell line, MDA-MB-231, which expresses PlGF and Flt-1, was used primarily because it measurably increases migration in the presence of PlGF within 3 h of exposure.

Materials and methods
=====================

Cell lines and treatments
-------------------------

Cell lines were from the American Type Culture Collection (Manassas, VA, USA). Treatment of cells with BP-1 (1 *μ*) and PlGF (1 n) was previously reported ([@bib49]). The concentration of inhibitors was actinomycin D (ActD, *de novo* transcription), 1 or 10 *μ*g ml^−1^ (migration assay), 1 *μ*g ml^−1^ (immunoblots); cycloheximide (CHX), 3 *μ*g ml^−1^ (*de novo* translation); PD98059 (PD98) (MEK pathway), 50 *μ*; LY294002, 2 *μ* (PI3K pathway) (all from Calbiochem, La Jolla, CA, USA), wortmannin (non-specific PI3K inhibitor), 5 n (Sigma, St Louis, MO, USA).

Migration assay
---------------

Spontaneous migration (wound) assays were performed as previously described ([@bib28]; [@bib35]; [@bib56]; [@bib49]) using cells treated with PlGF, BP-1, inhibitor, or with antibody (1 *μ*g ml^−1^). Cells were treated with PlGF either simultaneously with, or 15 min before inhibitors, as indicated. At the indicated time points up to 3 h, coverslips were stained, mounted, and examined microscopically by two blinded researchers. Five to ten × 100 fields per slide were evaluated by counting cells separated from the wound edges and that appeared to be migrating. In two instances, results were normalised by a constant factor (e.g., two-fold) to diminish inter-experimental variation. The results are reported as the average number of cells migrating into the wound per × 100 field±s.d. from 5 to 10 fields per coverslip; one to two coverslips per treatment per experiment, from two to five experiments, depending on the treatment.

Immunoblots
-----------

Immunoblot analysis was performed using standard methods ([@bib11]). In all, 10 *μ*g of protein per lane was loaded on gels; the primary antibody concentration was 1--5 *μ*g ml^−1^ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, or Cell Signaling Technology, Inc). (Beverly, MA, USA, <http://www.cellsignal.com>); biotinylated secondary antibody, 0.1--2 *μ*g ml^−1^ (Santa Cruz Biotechnology, Inc. or Sigma), along with a half-standard dilution of an avidin--biotin--HRP complex (Vector Laboratories, Inc., Burlingame, CA, USA). Blots were developed in Supersignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL, USA) and exposed on Kodak X-AR film (Sigma). Blots were then stripped (Immunopure IgG Elution Buffer, Pierce), and re-probed for actin or another marker.

Immunoblot signal was quantified by scanning densitometry (Un-Scan-It Automated Digitizing System Software, Silk Scientific Corp., Orem, UT, USA), using the total pixel density. Relative expression of each protein is presented as the densitometry units, or calculated as the ratio of signal density to actin density, or compared to untreated controls.

Immunofluorescence, immunohistochemistry, and detection of actin filament disruption
------------------------------------------------------------------------------------

Depolymerisation of the actin cytoskeleton was determined according to the method described by several groups ([@bib1]; [@bib24], [@bib25]; [@bib3]). Cells on coverslips were treated as indicated, fixed in 3.7% methanol-free formaldehyde (in PBS) for 15 min, followed by permeabilisation in 0.5% Triton X-100 (T-X-100) in PBS for 5 min, and blocked in 1% BSA in 0.1% T-X-100/PBS for 15 min. Cells were then labelled with 1 U FITC-labeled phalloidin (1 *μ*g ml^−1^) (Sigma), or labelled with both FITC-phalloidin and AlexaFluor594-DNase I (AF-DNase I) (Invitrogen, Carlsbad, CA, USA) (10 *μ*g ml^−1^) in 1% BSA/PBS for 20 min at room temperature in the dark.

Labelling of both F-actin (FITC-phalloidin) and G-actin (AF-DNase I) together corrects for differences in cell size or number per image, and thus aids in the quantification of changes in the polymerised actin fibres ([@bib8]; [@bib24]). Isoproterenol, which measurably depolymerised the actin cytoskeleton after 1 min (2 and 20 *μ*) (MDA-MB-231), was the depolymerisation control. Multiple views containing \>20 cells per × 400 microscopic field were captured at room temperature with Microfire software (Olympus America, Center Valley, PA, USA) with the exposure time, image-intensity gain, and enhancement held constant throughout to minimise intra- and inter-experimental variation. For each actin form, the number of pixels of a given fluorescence intensity was determined using Photoshop software (Adobe Systems, San Jose, CA, USA) at intensity values for AF-DNase I, 108±11; FITC-phalloidin, 159±10; non-cellular background, 7±4 (DNase I) or 15±4 (phalloidin) ([@bib8]; [@bib24]; [@bib37]).

Separate samples were permeabilised, blocked, and stained with antibodies (e.g., p-ERK1/2) at a concentration of 1 *μ*g ml^−1^. Primary antibody binding was detected by HRP-, FITC-, or PE-labeled secondary antibodies. The location of phosphorylated ERK (pERK) was determined for nuclear staining by counting cells with darkly stained nuclei in six to ten × 400 microscope fields at the wound edges *vs* total number of cells (average number of cells per treatment: 406±11). Blue counterstained nuclei were considered negative. Nuclei with intermediate staining were counted, did not vary substantially between samples, and so are not included in the analysis. Cells were considered positive for pERK in the periphery if 40% of the cellular border was moderately to heavily positive.

For both bright field and fluorescent detection, mounted coverslips were examined at × 100 and × 400 with an Olympus BH-2 microscope (Olympus × 10 objective lens numerical aperture (NA) 0.30 or × 40 objective, NA 0.70), and captured digitally with an Olympus U-PMTVC camera using Microfire software (Olympus America).

Statistics
----------

Values are expressed as the mean±s.d. or s.e.m. to summarise results. One-way analysis of variance or Student\'s *t*-test was used to determine the *P*-values. *P*⩽0.05 was considered significant.

Results
=======

Immediate migration response is independent of *de novo* mRNA or protein synthesis
----------------------------------------------------------------------------------

We reported previously that MDA-MB-231 human breast cancer cells incubated with exogenous PlGF at a concentration of 1 n attained significantly (analysis of variance) increased invasive potential (transwell) and motility (wound). MDA-MB-231 showed consistent and significantly increased motility of 1.5- to 2-fold within 3 h after 'wounding\' the cell monolayer. On the other hand, invasion was measurable at a later time point (20 h) for MDA-MB-231, and the two other model cell lines, MCF-7 and MDA-MB-468. Similar to MDA-MB-231, MCF-7 responded to PlGF with increased invasiveness in 24 h, but MDA-MB-468 was unresponsive at all time points ([@bib49]). As the purpose of this study was to document the immediate effect of PlGF on kinase activation within 1--3 h of exposure, spontaneous motility assays (wound) with MDA-MB-231 were used because of the rapid and measurable kinetics of PlGF-stimulated migration, and because this cell line is tumourigenic and metastatic in mice. Similar to 30--60% of primary breast cancers, MDA-MB-231 also expresses the PlGF receptor, Flt-1. In addition, it expresses NRP-1, an alternative PlGF receptor that is expressed by normal breast ([@bib2]; [@bib49]).

The rapid response of MDA-MB-231 to PlGF suggested independence from *de novo* transcription or translation. This was tested by simultaneous addition of ActD (10 *μ*g ml^−1^), or CHX (3 *μ*g ml^−1^) and PlGF to MDA-MB-231 motility assays. Neither treatment significantly inhibited PlGF-stimulated migration (1.3-fold ActD and 1.4-fold CHX) when compared with treatment with ActD or CHX alone ([Table 1](#tbl1){ref-type="table"}). These results suggest that because *de novo* mRNA and protein synthesis has minimal effects on the PlGF-mediated motility observed within 3 h of stimulation, activated intracellular kinases may mediate motility.

Intracellular signalling: pERK and the PI3K pathways
----------------------------------------------------

Cellular movement entails changes in the cytoskeleton, which can be mediated through activation of a number of intracellular pathways, several of which may co-operate ([@bib52]). Common targets of activated RTKs, which include the PlGF receptor Flt-1, are the ERKs and PI3K.

Activation (phosphorylation) of the ERK1/2 kinases was assessed by immunoblot, and it was found that PlGF mediates a 2- to 12.7-fold increase in phosphorylated ERK1/2 (pERK) (activated) in MDA-MB-231 and MCF-7 ([Figure 1A](#fig1){ref-type="fig"} shows representative immunoblots). On the other hand, MDA-MB-468 displayed decreased pERK after 1 h ([Figure 1A](#fig1){ref-type="fig"}). The ERK1/2 kinases are the *sole* substrates of mitogen-activated protein kinase kinase (MAPKK or MEK); therefore, the MEK-specific inhibitor, PD98059 (PD98), was used to distinguish the contribution of the ERK1/2 from other ERK kinases, and the p38MAPKs, which are not substrates of MEK. PD98 (50 *μ*) treatment ablated ERK phosphorylation when used alone or in the presence of PlGF (not shown, MDA-MB-231). PD98 also inhibited PlGF-stimulated migration of MDA-MB-231, as shown in [Table 1](#tbl1){ref-type="table"}. These results suggest a relationship between PlGF, increased motility, and the activity of the MEK/ERK1/2 pathway.

The PlGF cell surface receptors, Flt-1, and the glycosylphosphatidylinositol-linked co-receptor, NRP-1, are differentially expressed in normal breast tissue *vs* breast cancer. Soluble Flt-1, anti-PlGF antibody, and the Flt-1-antagonising peptide, BP-1, inhibited PlGF-stimulated cellular movement ([@bib49]). These findings, taken together with the ablation of cellular motility by ERK1/2 inhibition (PD98) shown in [Table 1](#tbl1){ref-type="table"}, suggest that ERK1/2 and Flt-1 participate in PlGF-driven breast cancer cell movement.

The specificity of ERK activation by PlGF was further demonstrated when lysates from anti-PlGF or anti-Flt-1 antibody-treated cells were probed for pERK by western blot analysis. Addition of either antibody inhibited ERK phosphorylation ([Figure 1A](#fig1){ref-type="fig"}), a result that further demonstrates the specificity of the PlGF-Flt-1-mediated phosphorylation of ERK.

Active ERK kinases translocate to the nucleus and to the cytoskeleton. As determined by immunohistochemistry, intranuclear pERK was abundant, even in untreated MDA-MB-231 cells, with 72--80% of nuclei staining heavily. The PlGF treatment consistently increased the percentage of positive nuclei to 85±2% (406±11 cells per treatment evaluated). Treatment of cells with the BP-1 peptide, combined with PlGF, significantly decreased the frequency of positive nuclei to 62±5% (*P*\<0.001) ([Figure 1B](#fig1){ref-type="fig"}). The pERK was also found in a dotted pattern at the cellular periphery (see Materials and Methods) and in the perinuclear region. The frequency of cells staining for peripheral pERK differed among treatment groups with PlGF almost doubling that of untreated cells (23±4 *vs* 12±3%, respectively, *P*\<0.001 PlGF *vs* untreated). Treatment with BP-1 prevented the PlGF-mediated increase in peripheral pERK (7±3% for PlGF+BP-1 (*P*\<0.001 *vs* PlGF-only)).

PlGF did not detectably direct another ERK kinase, ERK5, which also enhances cellular motility through disruption of cellular adhesion and disassembly of the actin cytoskeleton to the cellular periphery ([@bib3]) (not shown).

The ERK and the PI3K pathways may co-operate or oppose each other in particular cellular responses, including motility. To investigate the participation of PI3K pathways in PlGF-mediated motility, MDA-MB-231 cells were treated with inhibitors of the PI3K pathway.

Unlike the results obtained for ERK, motility was not inhibited by the non-specific PI3K inhibitor, wortmannin (5 n) (not shown), or with the more specific PI3K inhibitor, LY294002 (2 *μ*, MDA-MB-231) ([Table 1](#tbl1){ref-type="table"}). Phosphorylated Akt, a common downstream substrate of PI3K, was not increased or decreased by addition of PlGF (MCF-7, not shown). Therefore, this pathway was not detectably activated by PlGF, and most likely is not involved in PlGF-stimulated migration of breast cancer cells.

IF expression by breast cancer cell lines
-----------------------------------------

As PlGF-stimulated cellular motility and ERK activation were prevented by BP-1 and anti-Flt-1 antibody, it was concluded that PlGF may exert its effect on the cytoskeleton at least partially through pERK. ERK kinases interact with both the actin and the IFs of the cytoskeleton, including vimentin. Changes in IF type and quantity are associated with breast cancer aggressiveness and invasion. Normal breast epithelium does not express the mesenchymal IF protein, vimentin. Phosphorylated ERKs1/2 bind vimentin, stabilising ERK in its phosphorylated form, which in turn leads to rearrangement of the vimentin network ([@bib40]; [@bib23]).

To investigate the relationship of ERK1/2, PlGF, and IF expression in cellular motility, the relative amounts of vimentin and the CKs 8/18 and 19 were first assessed for three breast cancer cell lines (MDA-MB-231, -468, and MCF-7). Results are shown in [Figure 2A](#fig2){ref-type="fig"}. MDA-MB-231 expresses abundant vimentin, but it was undetectable in MDA-MB-468 and MCF-7 even after long exposures ([Figure 2A](#fig2){ref-type="fig"}). The immunoblots showed that MDA-MB-231, MCF-7, and MDA-MB-468 breast cancer cells all express CK19, but the latter two lines are also high expressers of CK8/18 ([Figure 2A](#fig2){ref-type="fig"}). The MCF-7 CK8/18 to actin ratio was slightly increased over the CK19 ratio, but both were abundantly expressed (3.9±0.6 *vs* 2.9±0.32). On the other hand, MDA-MB-231, an aggressive cell line that forms metastases from subcutaneous xenograft tumours, expressed six-fold greater CK19 than CK8/18 ([Figure 2A](#fig2){ref-type="fig"}). MDA-MB-468, also tumourigenic but non-metastasising, expressed high levels of the CKs but no vimentin.

Alterations in vimentin expression *vs* PlGF
--------------------------------------------

To assess whether PlGF would alter vimentin expression, MDA-MB-231 was stimulated with PlGF for 1--3 h, and the relative amount of vimentin was determined by immunoblot. Increased vimentin expression of 1.9- to 4-fold compared with the untreated control was detected at the 1-h time point ([Figure 2B](#fig2){ref-type="fig"}, *P*\<0.02). Addition of the peptide BP-1 to the PlGF-containing cultures resulted in a reversal of the PlGF-stimulated increase at 3 h (1.07 of untreated control) ([Figure 2B](#fig2){ref-type="fig"}).

To investigate this early effect of PlGF on vimentin expression mediated by *de novo* mRNA or protein synthesis, MDA-MB-231 cells were incubated with sub-toxic doses of ActD and CHX (1 and 3 *μ*g ml^−1^, respectively) to inhibit mRNA and protein synthesis, respectively. Lysates were assessed for vimentin at 30 min, 1 h, and 3 h. In these experiments incubation of MDA-MB-231 with ActD resulted in declining vimentin over 3 h. The CHX treatment, on the other hand, caused a 50% decrease in vimentin at 1 h, but after 1 h the amount of vimentin stabilised and did not decline significantly thereafter. As shown on the graph in [Figure 2C](#fig2){ref-type="fig"}, it appears that both *de novo* mRNA transcription and translation are involved in vimentin production, but in the absence of translation, a mechanism for stabilisation of vimentin is activated that prevents or slows its loss.

In further experiments investigating the influence of PlGF on vimentin expression, MDA-MB-231 cells were pre-incubated with PlGF for 15 min before addition of ActD or CHX. This resulted in persistence of vimentin, even in the presence of ActD or CHX ([Figure 2C](#fig2){ref-type="fig"}). Thus, it is probable that PlGF activates mechanisms that promote the stability of vimentin independently of mRNA or protein synthesis.

PlGF mediates stability of specific IF CKs
------------------------------------------

Just as expression of mesenchymal vimentin is associated with aggressive breast cancer, changes in the pattern of CK expression are also considered indicative of breast cancer aggressiveness and motility, and co-expression of CK19 and vimentin is indicative of poor clinical outcome ([@bib5]; [@bib6]). The effect of PlGF on CK expression was assayed, and it was found that PlGF did not influence the abundance of CK8/18 (not shown). However, after incubation for 1 h with PlGF, CK19 increased 1.5-fold over untreated controls (*P*=0.05) (MDA-MB-231, four experiments). Treatment with BP-1 measurably attenuated CK19 expression in PlGF-treated samples by 2 h (average 0.58±0.32 of PlGF-only, two experiments), suggesting that autocrine PlGF signalling, which was blocked by the peptide, may have a role in the maintenance of CK19 expression. A control peptide did not affect CK19 expression (not shown).

The antagonistic effect of BP-1 on CK19 expression could be due to interruption of PlGF-Flt-1-mediated stabilisation of CK19 protein. To further investigate the influence of PlGF on the stability of CK19, cells were treated with either ActD or CHX at the sub-toxic doses described above. Cumulative results are shown in [Figure 3A](#fig3){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"} shows representative blots. In the CHX-treated samples, CK19 diminished to 50% of initial levels by 30 min, remained at that level at the 1-h time point, after which it declined to very low levels by 3 h (as shown in [Figure 3A](#fig3){ref-type="fig"}). The ActD treatment also brought about a steady decrease in CK19 ([Figure 3A](#fig3){ref-type="fig"}). These results suggest that CK19 expression is regulated, in part, by transcription and translation.

In separate experiments, MDA-MB-231 was pre-treated with PlGF for 15 min before adding ActD or CHX. Pre-treatment prevented the decrease in CK19 seen with single-agent treatment, such that the CK19 levels remained higher than the untreated controls ([Figure 3A](#fig3){ref-type="fig"}). Thus, the effect of PlGF on CK19 seems to be independent of *de novo* transcription or translation, and may be related to the rate of degradation of CK19.

PlGF stimulates rearrangement of the actin cytoskeleton
-------------------------------------------------------

The microscopic appearance of PlGF-treated breast cancer cells stained for F-actin differed from untreated cells by the appearance of increased actin-rich punctate structures on the edges of the cells (not shown). This observation may be due to the re-organisation of the actin cytoskeleton as the cell becomes motile, and which has been documented for other growth factors and carcinomas, for example, epidermal growth factor ([@bib8]; [@bib19]). The state of the actin cytoskeleton was quantified by determination of the F-actin (filamentous, polymerised) to G-actin (non-polymerised) ratio using phalloidin and DNase I, which stain F-actin and G-actin, respectively, as described in Materials and methods. The ratio of F-actin to G-actin decreased to less than half of untreated controls, indicating actin cytoskeleton rearrangement on PlGF treatment ([Figure 4](#fig4){ref-type="fig"}). In contrast to the effect of PlGF alone, addition of the inhibitory peptide, BP-1, to PlGF-treated cultures prevented lowering of the F-actin to G-actin ratio associated with PlGF.

Discussion
==========

The purpose of this study was to analyse the early events triggered by PlGF in the responsive breast cancer cell, and elucidate how the peptide, BP-1, works in inhibiting cellular motility *in vitro*, and in preventing metastasis formation in xenograft models of breast cancer ([@bib49]). To carry out this, the effect of inhibitors on cellular motility, a pro-metastatic behaviour, was analysed. The results show that PlGF-driven breast tumour cell motility include the activation of ERK1/2 kinases, stabilisation of IF proteins, and re-organisation of the actin cytoskeleton. The PlGF specificity of these results was shown by their ablation with anti-Flt-1 antibody or BP-1.

The ERKs are activated by a number of different factors, including c-Src, the G-protein-linked kinase Raf, and MEK ([@bib3]; [@bib10]). Increased pERK stimulated by PlGF was reversed by treatment with BP-1 or a MEK-specific inhibitor. Ablation of MEK not only prevented pERK formation, but it also prevented PlGF-stimulated cellular migration. Thus, as the only known substrates of MEK are the ERK1/2 kinases, it can be concluded that PlGF-stimulated motility depends on activation of the ERKs by MEK. This does not eliminate other potential ERK activators, and preliminary data (not shown) suggest that Raf participates in PlGF effects as well.

While this study was in progress, another report investigated PlGF-mediated migration of leukaemia cells ([@bib7]). Our findings are in agreement with this report, in that we found no evidence of Akt involvement in PlGF-mediated breast cancer cell movement. However, unlike Casalou *et al*, little evidence of p38 MAPK involvement in PlGF-mediated breast cancer cell movement was found because movement was abrogated by inhibition of MEK, which does not activate p38 MAPK. Therefore, it is unlikely that p38 MAPK contributes substantially to the movement of breast cancer cells in the presence of PlGF. Another point of difference was the finding that VEGF had little to no effect on breast cancer cell migration ([@bib49]). This contrasts with the results obtained by Casalou *et al* for leukaemia cells. These differences may be due to different effects of VEGF and PlGF on cancers of epithelial origin, such as breast cancer, in contrast to cancers of hematopoietic origin, where the function of VEGF and PlGF may be redundant.

When activated, the ERK kinases localise to the nucleus or to focal adhesions where they are associated with motility by interaction with cytoskeletal substrates, including IF proteins, the actin cytoskeleton, and myosin light chain kinase ([@bib59]; [@bib42]; [@bib1]; [@bib39]; [@bib57]). This study presented evidence that PlGF promoted translocation of pERK1/2 to the cellular periphery, and so there it may function to increase motility.

Although CK18 and CK19 are expressed by normal breast epithelium, their expression is often dysregulated in breast cancers ([@bib16]; [@bib4]). Aggressive MDA-MB-231 displays a pattern of predominant CK19 with little or no CK18, whereas this is not the case for MCF-7 or MDA-MB-468, which both produce abundant CK18 (and CK19). Human breast cancers expressing high levels of CK18 (without vimentin), similar to MCF-7 or MDA-MB-468, are less likely to recur. In addition, MDA-MB-231 transfected with CK18 obtains an epithelial phenotype, reduces aggressiveness in tumour growth, and loses vimentin expression ([@bib6]). On the basis of the results of this study, in which CK19 and vimentin expression rose on PlGF stimulation, it is possible that RTK activation, such as Flt-1, stimulates co-expression of CK19 and vimentin.

Likewise, vimentin, a mesenchymal IF protein not expressed by normal breast cells, is associated with poorer clinical outcomes and resistance to apoptosis and drugs ([@bib58]; [@bib46]; [@bib55]), as well as increased metastasis and invasion ([@bib20]; [@bib51]; [@bib44]; [@bib27]; [@bib43]). [@bib34] showed that the aggressiveness of MDA-MB-231 depends on vimentin expression, because its ablation impaired migration and invasion. Our data show that disrupting PlGF or Flt-1 signalling with antibody or BP-1 depressed vimentin, CK19 expression, and motility in MDA-MB-231. Thus, in the case of MDA-MB-231 and perhaps other breast cancers, PlGF, or other abnormally expressed growth factors, may maintain the high CK19 and vimentin levels necessary for motility and invasion. The results also suggest that PlGF does this by stabilising the proteins independently of ongoing transcription and translation, and that, because of their concurrent increase, both factors are controlled by intersecting or common pathways, some of which are regulated by PlGF.

Flt-1 has been considered a cell surface-bound receptor ([@bib53]; [@bib32]); however, nuclear expression that delivered intracrine signals promoting breast cancer cell survival through VEGF was reported by [@bib30]. Our previous report indicated that exogenous PlGF, rather than VEGF, promoted cellular movement, and that soluble Flt-1 and anti-PlGF antibody blocked migration. In this study, we show that exogenous anti-Flt-1 attenuates PlGF-driven phosphorylation of ERK also. Except for the non-significant increase in nuclear translocation of pERK with PlGF treatment, there is no indication that the PlGF interactions leading to activation of ERK reported herein occurred in the nucleus. In almost all cases, ERKs are activated by factors associated with the inner leaflet of the plasma membrane and cell surface receptors. Therefore, it can be concluded that PlGF stimulates motility by interaction with cell surface Flt-1, rather than nuclear Flt-1. The intracrine and cell surface functions of Flt-1, one conferring survival and the other motility through PlGF, are not mutually exclusive, and both promote metastasis.

In summary, this study describes for the first time, the effect of the growth factor, PlGF, on the activation of key kinases, which participate in increased cellular motility, a behaviour associated with metastasis rather than tumour growth and tumour cell proliferation. In other human cancers, ectopically expressed growth factors may also drive metastasis by mechanisms similar to those shown here for PlGF. For the breast cancer cell lines studied, the specificity of the kinase activation and increased migration was verified with antibody against both PlGF and Flt-1. The peptide, BP-1, abrogates PlGF-driven cellular motility and several of the PlGF-mediated changes in intracellular signalling, and this may, in part, explain its anti-tumour activity.

We thank Dr David V Gold for helpful comments on this paper. This work was supported, in part, by the New Jersey Department of Health and Senior Services Grant 07-1824-FS-N-0 (DMG).

![Activation of the extracellular-regulated kinases (ERKs) by PlGF, and inhibition by BP-1 and antibody treatment. (**A**) Representative blots of cell lines treated as shown. Placental growth factor (PlGF) (1 nM) (P); BP-1 (1 *μ*) (**B**); anti-PlGF (a-P), or anti-Flt-1 (a-F), or C (irrelevant antibody), 1 *μ*g ml^−1^. MDA-MB-468: U, untreated; P30 min, PlGF treatment at 30-min time point; P2 h, PlGF treatment at 2-h time point; P24 h, PlGF at 24-h time point. MDA-MB-231 and MDA-MB-468 actin controls are from the same blot; MCF-7 actin is from a separate, identical blot. (**B**) BP-1 depletes nuclear phosphorylated ERK (pERK) in PlGF-treated cells. Micrographs of immunohistochemical staining of pERK in MDA-MB-231 cells. Treatments are shown. Original magnification × 400, bar 50 *μ*m.](6605746f1){#fig1}

![Expression of cytokeratins (CKs) and vimentin by MDA-MB-231, MCF-7, and MDA-MB-468; and stabilisation of vimentin expression by PlGF. (**A**) Immunoblots for vimentin, CKs 8/18 and 19 in MDA-MB-231 (lane 1), MCF-7 (lane 2), and MDA-MB-468 (lane 3). Blots were loaded with 10 *μ*g protein per lane, and probed simultaneously for each factor. Actin is from a separate, identical blot. (**B**) Vimentin expression at 3 h after addition of PlGF (1 n) or peptide BP-1 (1 *μ*). Black bars represent vimentin±s.e.m.; white bars, actin±s.e.m. (immunoblot densitometry readings). Vimentin expression increased 1.59±0.33-fold with PlGF treatment, and by 0.97±0.09-fold for PlGF+BP-1 (*vs* Unt (untreated)±s.d.). Actin variation was 1.04±0.13. ^\*^*P*\<0.02 (analysis of variance): *n*=3 experiments. (**C**) Vimentin expression following pre-treatment with PlGF before adding actinomycin D (ActD) or CHX *vs* single-agent treatment (*n*=2 experiments, each treatment). The table below shows the ratios at 1 and 3 h.](6605746f2){#fig2}

![Stabilisation of cytokeratin (CK) expression by PlGF, with disruption by BP-1. (**A**) CK19 expression in MDA-MB-231 pre-treated with PlGF before adding actinomycin D (ActD) or CHX *vs* either inhibitor alone (*n*=2 experiments each treatment). (**B**) Upper panel: representative blot showing MDA-MB-231 CK19 expression following treatment with ActD (1 *μ*g ml^−1^) or CHX (3 *μ*g ml^−1^) alone. (30-min, 1-, and 3-h time points are shown: Un, untreated; P, PlGF-only; A, ActD; C, CHX at each time point.) Lower panel: representative blot showing CK19 expression when cells were pre-treated with PlGF 15 min before adding ActD or CHX. (30 min, 1 or 3 h after inhibitor was added: Un, untreated; P, PlGF-only; P/A, PlGF pre-treated, followed by ActD; P/C, PlGF pre-treated, followed by CHX for the times indicated.)](6605746f3){#fig3}

![Placental growth factor (PlGF) induces rearrangement of the actin cytoskeleton, and reversal by BP-1. The ratio of F-actin to G-actin changes with PlGF or epidermal growth factor (EGF) treatment (1 n). Results are shown as average of ratios±s.d. ^\*^*P*\<0.05 (analysis of variance): *n*=3 experiments (epidermal growth factor (EGF), one experiment).](6605746f4){#fig4}

###### PlGF-stimulated cellular motility is independent of *de novo* mRNA and protein synthesis, and inhibition of MEK/ERK pathway prevents PlGF-stimulated migration

  **Treatment**                    **Average number of migrating cells per × 100 field±s.d.**
  -------------------------------- ------------------------------------------------------------
  Untreated                        4.3±2.5
  PlGF (1 n)                       7.4±2.8^\*^
  PD98059 (50 *μ*)                 4.0±2.3
  PD98059+PlGF                     3.7±3.2
  LY294002 (2 *μ*)                 7.5±3.3^\*^
  LY294002+PlGF                    7.6±2.6^\*^
                                    
  Untreated                        8.5±3.9
  PlGF (1 n)                       11.2±4.5^\*^
  Actinomycin D (10 *μ*g ml^−1^)   7.5±4.0
  Actinomycin D+PlGF               9.5±4.1^\*^
  Cycloheximide (3 *μ*g ml^−1^)    7.1±4.8
  Cycloheximide+PlGF               9.9±5.3^\*^

Abbreviations: ERK=extracellular-regulated kinase; MEK=mitogen-activated protein kinase kinase; PlGF=placental growth factor.

Five to ten × 100 fields on duplicate coverslips were evaluated for migrating cells by two researchers. Results were averaged and the s.d. was determined. The 3-h time point from two to five separate experiments is shown. ^\*^*P*\<0.02 compared with control (PlGF *vs* untreated; actinomycin D+PlGF *vs* actinomycin D; cycloheximide+PlGF *vs* cycloheximide; LY294002 or LY294002+PlGF *vs* untreated).
